{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:26:53Z","timestamp":1790029613721,"version":"4.0.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"AbbVie GK"},{"name":"Asahi-Kasei"},{"name":"Ayumi"},{"DOI":"10.13039\/100010795","name":"Chugai","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Janssen K.K"},{"name":"Ono"},{"DOI":"10.13039\/100015990","name":"Sanofi K.K","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015990","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Teijin Healthcare"},{"name":"UCB Japan"},{"name":"CAC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s10067-021-05609-7","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T20:02:49Z","timestamp":1611950569000},"page":"2673-2680","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2426-1024","authenticated-orcid":false,"given":"Kosuke","family":"Ebina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-3154","authenticated-orcid":false,"given":"Toru","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6831-8205","authenticated-orcid":false,"given":"Yuichi","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0810-4221","authenticated-orcid":false,"given":"Wataru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9241-060X","authenticated-orcid":false,"given":"Motomu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7896-3937","authenticated-orcid":false,"given":"Koichi","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3120-1273","authenticated-orcid":false,"given":"Akira","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3021-183X","authenticated-orcid":false,"given":"Sadao","family":"Jinno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8000-3196","authenticated-orcid":false,"given":"Ryota","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7244-7715","authenticated-orcid":false,"given":"Yonsu","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7299-2884","authenticated-orcid":false,"given":"Hideki","family":"Amuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0065-929X","authenticated-orcid":false,"given":"Tohru","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1927-1295","authenticated-orcid":false,"given":"Ayaka","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0773-7238","authenticated-orcid":false,"given":"Masaki","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1408-7851","authenticated-orcid":false,"given":"Makoto","family":"Hirao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3620-8412","authenticated-orcid":false,"given":"Yasutaka","family":"Okita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4749-7117","authenticated-orcid":false,"given":"Atsushi","family":"Kumanogoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8964-4229","authenticated-orcid":false,"given":"Ken","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,29]]},"reference":[{"key":"5609_CR1","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, Muller-Ladner U, Mysler EF, da Silva JAP, Poor G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685\u2013699","journal-title":"Ann Rheum Dis"},{"key":"5609_CR2","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1136\/annrheumdis-2011-200882","volume":"71","author":"SM Du Pan","year":"2012","unstructured":"Du Pan SM, Scherer A, Gabay C, Finckh A (2012) Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients. Ann Rheum Dis 71:997\u2013999","journal-title":"Ann Rheum Dis"},{"key":"5609_CR3","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/rheumatology\/keu158","volume":"53","author":"EG Favalli","year":"2014","unstructured":"Favalli EG, Biggioggero M, Marchesoni A, Meroni PL (2014) Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology (Oxford) 53:1664\u20131668","journal-title":"Rheumatology (Oxford)"},{"key":"5609_CR4","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13075-020-02232-w","volume":"22","author":"K Ebina","year":"2020","unstructured":"Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K, Takeuchi T, Shiba H, Son Y, Amuro H, Onishi A, Akashi K, Hara R, Katayama M, Yamamoto K, Kumanogoh A, Hirao M (2020) Drug retention of 7 biologics and tofacitinib in biologics-naive and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study. Arthritis Res Ther 22:142","journal-title":"Arthritis Res Ther"},{"key":"5609_CR5","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1093\/rheumatology\/key361","volume":"58","author":"P Emery","year":"2019","unstructured":"Emery P, Rondon J, Parrino J, Lin Y, Pena-Rossi C, van Hoogstraten H, Graham NMH, Liu N, Paccaly A, Wu R, Spindler A (2019) Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis. Rheumatology (Oxford) 58:849\u2013858","journal-title":"Rheumatology (Oxford)"},{"key":"5609_CR6","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","volume":"13","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL (2017) The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 13:234\u2013243","journal-title":"Nat Rev Rheumatol"},{"key":"5609_CR7","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00393-018-0531-5","volume":"78","author":"SC Bae","year":"2019","unstructured":"Bae SC, Lee YH (2019) Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Z Rheumatol 78:559\u2013567","journal-title":"Z Rheumatol"},{"issue":"2628-2641","key":"5609_CR8","volume":"38","author":"MC Vieira","year":"2016","unstructured":"Vieira MC, Zwillich SH, Jansen JP, Smiechowski B, Spurden D, Wallenstein GV (2016) Tofacitinib versus biologic treatments in patients with active rheumatoid arthritis who have had an inadequate response to tumor necrosis factor inhibitors: results from a network meta-analysis. Clin Ther 38(2628-2641):e2625","journal-title":"Clin Ther"},{"key":"5609_CR9","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/art.24463","volume":"61","author":"SM Du Pan","year":"2009","unstructured":"Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A (2009) Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 61:560\u2013568","journal-title":"Arthritis Rheum"},{"key":"5609_CR10","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/acr.22788","volume":"68","author":"EG Favalli","year":"2016","unstructured":"Favalli EG, Pregnolato F, Biggioggero M, Becciolini A, Penatti AE, Marchesoni A, Meroni PL (2016) Twelve-year retention rate of first-line tumor necrosis factor inhibitors in rheumatoid arthritis: real-life data from a local registry. Arthritis Care Res 68:432\u2013439","journal-title":"Arthritis Care Res"},{"key":"5609_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/rheumatology\/keq209","volume":"50","author":"KL Hyrich","year":"2011","unstructured":"Hyrich KL, Watson KD, Lunt M, Symmons DP (2011) Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology (Oxford) 50:117\u2013123","journal-title":"Rheumatology (Oxford)"},{"key":"5609_CR12","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1136\/annrheumdis-2013-204128","volume":"74","author":"M Neovius","year":"2015","unstructured":"Neovius M, Arkema EV, Olsson H, Eriksson JK, Kristensen LE, Simard JF, Askling J (2015) Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis 74:354\u2013360","journal-title":"Ann Rheum Dis"},{"key":"5609_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216624","volume":"14","author":"K Ebina","year":"2019","unstructured":"Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M, Onishi A, Nagai K, Son Y, Amuro H, Yamamoto K, Maeda Y, Murata K, Jinno S, Takeuchi T, Hirao M, Kumanogoh A, Yoshikawa H (2019) Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study. PLoS One 14:e0216624","journal-title":"PLoS One"},{"key":"5609_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13075-019-1880-4","volume":"21","author":"K Ebina","year":"2019","unstructured":"Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M, Onishi A, Nagai K, Son Y, Amuro H, Yamamoto K, Maeda Y, Murata K, Jinno S, Takeuchi T, Hirao M, Kumanogoh A, Yoshikawa H (2019) Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study. Arthritis Res Ther 21:91","journal-title":"Arthritis Res Ther"},{"key":"5609_CR15","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1007\/s10067-020-05015-5","volume":"39","author":"K Ebina","year":"2020","unstructured":"Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K, Takeuchi T, Nagai K, Son Y, Amuro H, Onishi A, Jinno S, Hara R, Katayama M, Yamamoto K, Kumanogoh A, Hirao M (2020) Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study. Clin Rheumatol 39:2563\u20132572","journal-title":"Clin Rheumatol"},{"key":"5609_CR16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13075-018-1673-1","volume":"20","author":"M Hashimoto","year":"2018","unstructured":"Hashimoto M, Furu M, Yamamoto W, Fujimura T, Hara R, Katayama M, Ohnishi A, Akashi K, Yoshida S, Nagai K, Son Y, Amuro H, Hirano T, Ebina K, Uozumi R, Ito H, Tanaka M, Ohmura K, Fujii T, Mimori T (2018) Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study. Arthritis Res Ther 20:165","journal-title":"Arthritis Res Ther"},{"key":"5609_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315\u2013324","journal-title":"Arthritis Rheum"},{"key":"5609_CR18","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580\u20131588","journal-title":"Ann Rheum Dis"},{"key":"5609_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194130","volume":"13","author":"K Ebina","year":"2018","unstructured":"Ebina K, Hashimoto M, Yamamoto W, Ohnishi A, Kabata D, Hirano T, Hara R, Katayama M, Yoshida S, Nagai K, Son Y, Amuro H, Akashi K, Fujimura T, Hirao M, Yamamoto K, Shintani A, Kumanogoh A, Yoshikawa H (2018) Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study. PLoS One 13:e0194130","journal-title":"PLoS One"},{"key":"5609_CR20","first-page":"939","volume":"74","author":"Y Kawahito","year":"2016","unstructured":"Kawahito Y (2016) Guidelines for the management of rheumatoid arthritis. Nihon Rinsho 74:939\u2013943","journal-title":"Nihon Rinsho"},{"key":"5609_CR21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3109\/s10165-009-0197-6","volume":"19","author":"R Koike","year":"2009","unstructured":"Koike R, Harigai M, Atsumi T, Amano K, Kawai S, Saito K, Saito T, Yamamura M, Matsubara T, Miyasaka N (2009) Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol 19:351\u2013357","journal-title":"Mod Rheumatol"},{"key":"5609_CR22","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3109\/s10165-007-0626-3","volume":"17","author":"R Koike","year":"2007","unstructured":"Koike R, Takeuchi T, Eguchi K, Miyasaka N (2007) Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol 17:451\u2013458","journal-title":"Mod Rheumatol"},{"key":"5609_CR23","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48:452\u2013458","journal-title":"Bone Marrow Transplant"},{"key":"5609_CR24","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s12272-015-0569-8","volume":"38","author":"GW Kim","year":"2015","unstructured":"Kim GW, Lee NR, Pi RH, Lim YS, Lee YM, Lee JM, Jeong HS, Chung SH (2015) IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future. Arch Pharm Res 38:575\u2013584","journal-title":"Arch Pharm Res"},{"key":"5609_CR25","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/acr2.11188","volume":"2","author":"P Emery","year":"2020","unstructured":"Emery P, van Hoogstraten H, Thangavelu K, Mangan E, St John G, Verschueren P (2020) Subcutaneous sarilumab in patients with rheumatoid arthritis who previously received subcutaneous sarilumab or intravenous tocilizumab: an open-label extension of a randomized clinical trial. ACR Open Rheumatol 2:672\u2013680","journal-title":"ACR Open Rheumatol"},{"key":"5609_CR26","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00393-020-00750-1","volume":"79","author":"YH Lee","year":"2020","unstructured":"Lee YH, Song GG (2020) Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis. Z Rheumatol 79:785\u2013796","journal-title":"Z Rheumatol"},{"key":"5609_CR27","doi-asserted-by":"publisher","unstructured":"Lee YH, Song GG (2020) Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs. Z Rheumatol. https:\/\/doi.org\/10.1007\/s00393-020-00796-1","DOI":"10.1007\/s00393-020-00796-1"},{"key":"5609_CR28","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s12325-019-00912-x","volume":"36","author":"E Choy","year":"2019","unstructured":"Choy E, Freemantle N, Proudfoot C, Chen CI, Pollissard L, Kuznik A, van Hoogstraten H, Mangan E, Carita P, Huynh TM (2019) Indirect treatment comparison of the efficacy and safety of sarilumab monotherapy in rheumatoid arthritis patients with inadequate response to conventional disease-modifying antirheumatic drugs. Adv Ther 36:817\u2013827","journal-title":"Adv Ther"},{"key":"5609_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000798","volume":"5","author":"E Choy","year":"2019","unstructured":"Choy E, Freemantle N, Proudfoot C, Chen CI, Pollissard L, Kuznik A, Van Hoogstraten H, Mangan E, Carita P, Huynh TM (2019) Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor alpha inhibitors: systematic literature review and network meta-analyses. RMD Open 5:e000798","journal-title":"RMD Open"},{"key":"5609_CR30","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/BOR.0000000000000470","volume":"30","author":"LA Ridgley","year":"2018","unstructured":"Ridgley LA, Anderson AE, Pratt AG (2018) What are the dominant cytokines in early rheumatoid arthritis? Curr Opin Rheumatol 30:207\u2013214","journal-title":"Curr Opin Rheumatol"},{"key":"5609_CR31","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1136\/annrheumdis-2016-210297","volume":"76","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Choy E, Kivitz A, Ogata A, Bao M, Nomura A, Lacey S, Pei J, Reiss W, Pethoe-Schramm A, Mallalieu NL, Wallace T, Michalska M, Birnboeck H, Stubenrauch K, Genovese MC (2017) Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. Ann Rheum Dis 76:1078\u20131085","journal-title":"Ann Rheum Dis"},{"key":"5609_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000363","volume":"3","author":"C Takahashi","year":"2017","unstructured":"Takahashi C, Kaneko Y, Okano Y, Taguchi H, Oshima H, Izumi K, Yamaoka K, Takeuchi T (2017) Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study. RMD Open 3:e000363","journal-title":"RMD Open"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05609-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05609-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05609-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T16:06:22Z","timestamp":1639584382000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05609-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,29]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["5609"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05609-7","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,29]]},"assertion":[{"value":"17 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The representative facility of this registry was Kyoto University, and this observational study was conducted in accordance with the Declaration of Helsinki, with the approval of the ethics committees of the following seven institutes: Kyoto University (2016-03-24\/approval No. R053), Osaka University (2015-11-04\/approval No. 15300), Osaka Medical College (2014-07-14\/approval No. 1529), Kansai Medical University (2017-11-21\/approval No. 2014625), Kobe University (2015-03-20\/approval No. 1738), Nara Medical University (2018-01-23\/approval No. 1692), and Osaka Red Cross Hospital (2015-09-01\/approval No. 644). The board of the Osaka University Hospital Ethics Committee waived the requirement for patient informed consent because of the anonymous nature of the data. Written informed consent was obtained from the participants in other institutes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The board waived the requirement for patient informed consent by posting the opt-out information in the hospitals\u2019 home page.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for participation and publication"}},{"value":"KE is affiliated with the Department of Musculoskeletal Regenerative Medicine, Osaka University, Graduate School of Medicine, which is supported by Taisho. KE has received research grants from Abbie, Asahi-Kasei, Astellas, Chugai, Eisai, Mitsubishi-Tanabe, Ono Pharmaceutical, Teijin Pharma, and UCB Japan. KE has received payments for lectures from Abbie, Asahi-Kasei, Astellas, Ayumi, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Janssen, Mitsubishi-Tanabe, Ono Pharmaceutical, Pfizer, Sanofi, and UCB Japan. TH received a research grant and\/or speaker fee from Astellas, Chugai, GlaxoSmithKline, Nippon Shinyaku, and Eisai. YM received a research grant and\/or speaker fee from Eli Lilly, Chugai, Pfizer, Bristol-Myers Squibb, and Mitsubishi-Tanabe. MHashimoto and KM are affiliated with a department that is financially supported by four pharmaceutical companies (Asahi-Kasei, Mitsubishi-Tanabe, Chugai, Ayumi, and UCB Japan) and the city government (Nagahama City). MHashimoto received a research grant and\/or speaker fee from Mitsubishi-Tanabe, Eisai, Eli Lilly, and Bristol-Myers Squibb. KM received a speaker fee from Eisai. TT is affiliated with a department that is financially supported by six pharmaceutical companies (Mitsubishi-Tanabe, Chugai, Ayumi, Astellas, Eisai, and Takeda). TT received a research grant from Chugai, cover letter and a speaker fee from Astellas, Chugai, Eisai, Mitsubishi-Tanabe, AbbVie, Bristol-Myers Squibb, Ayumi, Daiichi Sankyo, Eisai, Takeda, and Asahi-Kasei. AO received a speaker fee from Chugai, Ono Pharmaceutical, Eli Lilly, Mitsubishi-Tanabe, Asahi-Kasei, and Takeda. SJ has received speaking fees from AbbVie, Asahi-Kasei, Bristol-Myers Squib, Chugai, Eisai, Eli Lilly, Janssen Pharmaceutical, Mitsubishi-Tanabe, and Ono Pharmaceutical. RH received a speaker fee from AbbVie. MHirao received a speaker fee from Astellas, Ono Pharmaceutical, Eli Lilly, Mitsubishi-Tanabe, Pfizer, Ayumi, and Takeda. AK received a research grant and\/or speaker fee from Mitsubishi-Tanabe, Chugai, Eisai, Asahi-Kasei, Astellas, AbbVie, Bristol-Myers Squibb, Ono Pharmaceutical, and Pfizer. KN has received a research grant from Astellas, and supervises the Department of Musculoskeletal Regenerative Medicine, Osaka University, Graduate School of Medicine, which is supported by Taisho. WY, YS, HA, AY, MK, KY, and YO have no financial conflicts of interest to disclose concerning this manuscript. These companies had no role in the study design, data collection, data analysis, data interpretation, and preparation of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}